| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
With the recent development of highly potent and safe direct antiviral agents (DAAs), viral response (SVR) rate in HCV patients has been significantly improved. Therapeutic effect of PEG-IFN + RBV + NS3-4 protease inhibitor (TVR / SMV) was associated is a PEG-IFN + RBV, associated with HCV NS5A interferon sensitivity determining region (ISDR), -interferon/ribavirin resistance determining region (IRRDR) and core amino acid mutations (R70Q).Also R70Q mutation was associated with IL28B SNP related to IFN response.We revealed that drug resistance mutations to DAA is existed in the DAA naive cases, it was often found in IFN-sensitive strains.In the analysis by the next generation sequencer, HCV was a collection of a large number of variants (quasispecies), drug resistance mutations emerged from the wild-type strain, and Composition of major population greatly changed as the acquired resistant and altered composition were maintained thereafter.
|
